Cirrhotic Ascites
Conditions
Interventions
Interventin group:On Day 1, 10mg of Empagliflozin was taken orally in the morning, and the observation continued for 4 days.
Sponsors
Baoding People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Age 18 years or older. 2.Body weight of at least 50 kg, with a Body Mass Index (BMI) between 18 and 35. 3.Diagnosis of decompensated liver cirrhosis with ascites. Participants must have been treated with spironolactone and furosemide in the past three months, with no dose adjustment exceeding 100% or a reduction of more than 50%. 4.Diuretic doses must have been stable for the two weeks prior to enrollment. 5.Diagnosis of Type 2 Diabetes Mellitus, with no current use of SGLT2 inhibitors. 6.Estimated Glomerular Filtration Rate (eGFR) =60 mL/min/1.73m². 7.Capable of providing independent, written informed consent.
Exclusion criteria
Exclusion criteria: Any of the following conditions will result in the exclusion of the subject from the clinical trial: 1.Systolic blood pressure less than 95 mmHg or diastolic blood pressure less than 60 mmHg. 2.History of esophageal or gastric variceal bleeding in the past 1 month. 3.Development of grade II or higher hepatic encephalopathy in the past 1 month. 4.Late-stage liver cancer. 5.Use of SGLT2 inhibitors in the past month. 6.Significant alcohol or drug abuse history in the past six months. 7.Alcohol consumption within two weeks prior to enrollment, or use of any SGLT2 inhibitors in the past three months. 8.Model for End-Stage Liver Disease (MELD) score greater than 20 or estimated median survival less than six months. 9.Hemoglobin level below 7 g/dL. 10.Use of diuretics or vasopressin receptor antagonists other than spironolactone and furosemide within two weeks prior to enrollment, such as tolvaptan or thiazide diuretics. 11.Left ventricular ejection fraction less than 40% or B-type natriuretic peptide (BNP) level greater than 1000 ng/mL in the past three months. 12.Any urinary tract infection (e.g., pyelonephritis or cystitis) in the past three months, or presence of current urinary tract infection detected during screening. 13.Currently participating in another clinical trial or study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sodium excretion in urine.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary glucose excretion;Urine volume; | — |
Countries
China
Contacts
Public ContactRongya Shi
Baoding People's Hospital
Outcome results
None listed